Safety and Efficacy Study of NFC-1 in Subjects Aged 12-17 Years With 22q11.2DS & Associated Neuropsychiatric Conditions

NCT02895906 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

2

Enrollment

INDUSTRY

Sponsor class

Conditions

22q11.2 Deletion Syndrome

Interventions

DRUG: NFC-1

Sponsor

Aevi Genomic Medicine, LLC, a Cerecor company